October 28, 2026 Herpes Product Name & Imagery Cited in Warning Letter Takeaway - Product names & images can communicate disease claims
October 21, 2026 Amanita Safety Concerns Lead to Another Warning Letter Takeaway - Submitting an NDI notification does not replace adequate safety support
October 14, 2026 Baby Monitor Claims Attract NAD Scrutiny Takeaway - Review what your marketing implies, not just what it says
October 7, 2026 Amazon and Walmart Receive Another Round of FDA Warning Letters Takeaway - Review website navigation, marketplace listings, and older social posts for compliance
September 30, 2026 Ingredient Studies Don’t Automatically Add Up to a Finished-Product Claim Takeaway - Ingredient studies may support carefully qualified claims
September 23, 2026 Peptide NDI Safety Concerns Lead to Warning Letter Takeaway - Submitting an NDIN does not establish product safety
September 16, 2026 Dietary Supplement GMP Sanitation Citations Takeaway - Properly written SOPs are essential for compliance
September 9, 2026 “#1” Pet Product Claims Attract NAD Scrutiny Takeaway - Support the exact claim consumers are likely to take away
September 2, 2026 “Made in USA” Claims Draw FTC Warning Letters Takeaway - Review country-of-origin claims across all marketing
August 26, 2026 GMP Inspection Surfaces Alleged Record Falsification Takeaway - Following good documentation practices is a cornerstone of compliance
August 12, 2026 When Puffery Claims Become Performance Claims Takeaway - Review all marketing in context